UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000037395
Receipt number R000042634
Scientific Title Prospective Cohort Study of Endocrine Therapy with Abemaciclib for Chemotherapy-Treated Metastatic Breast Cancer
Date of disclosure of the study information 2019/11/01
Last modified on 2024/02/01 18:11:14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prospective Cohort Study of Endocrine Therapy with Abemaciclib for Chemotherapy-Treated Metastatic Breast Cancer

Acronym

Abemaciclib cohort study

Scientific Title

Prospective Cohort Study of Endocrine Therapy with Abemaciclib for Chemotherapy-Treated Metastatic Breast Cancer

Scientific Title:Acronym

Abemaciclib cohort study

Region

Japan


Condition

Condition

Breast cancer

Classification by specialty

Hematology and clinical oncology Breast surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To clarify the efficacy and safety of combination therapy with endocrine agents and abemaciclib for chemotherapy-treated metastatic breast cancer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Progression-Free Survival

Key secondary outcomes

Overall Survival, Time to Treatment Failure, Response Rate, Clinical Benefit Rate, and Adverse Events


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

1)Women 20 years older who are diagnosed with histologically confirmed primary breast cancer.
2)Women whose breast cancer is estrogen receptor ER positive and human epidermal growth factor receptor 2 HER2 negative.
3)Women who are diagnosed with difficult to treat metastatic breast cancer.
4)Women with a history of chemotherapy after diagnosis of metastatic breast cancer.
5)Women who plan to receive treatment with abemaciclib.
6)Women who are scheduled to start abemaciclib treatment from 21 days or later after the completion of the previous chemotherapy and 14 days or later after the completion of radiotherapy.
7)Women with no recent history of treatment with CDK4/6 inhibitors.
8)Women with no previous history of treatment with abemaciclib. women with an ECOG PS of 0 2.
9)Women whose vital organ function is normal.
10)Women from whom written informed consent to participate in the study is obtained.
Women who meet any of the following exclusion criteria are excluded.


Key exclusion criteria

Exclusion Criteria
1)Women for whom endocrine therapy is not indicated.
2)Women who require oxygen inhalation because of dyspnea under resting conditions.
3)Women who have previous history of gastrectomy or small bowel resection, except for mucosal resection.
4)Women who have Crohns disease, ulcerative colitis, or chronic diarrhea of Grade 2 or higher.
5)Women who are pregnant or nursing.
6)Women undergoing treatment for bacterial or fungal infection.
7)Women who have active hepatitis B or C.
8)Women who have serious cardiac disease.
9)Women whose primary care physicians considered that they are unsuitable for inclusion in this study.

Target sample size

300


Research contact person

Name of lead principal investigator

1st name Kazutaka
Middle name
Last name Narui

Organization

Yokohama City University Medical Center

Division name

Breast and Thyroid Surgery

Zip code

232-0024

Address

4-57 Urafune, Minami-ku, Yokohama 232-0024

TEL

045-261-5656

Email

nr1@gc5.so-net.ne.jp


Public contact

Name of contact person

1st name Kazutaka
Middle name
Last name Narui

Organization

Yokohama City University Medical Center

Division name

Breast and Thyroid Surgery

Zip code

232-0024

Address

4-57 Urafune, Minami-ku, Yokohama 232-0024

TEL

045-261-5656

Homepage URL


Email

nr1@gc5.so-net.ne.jp


Sponsor or person

Institute

CSPOR-BC

Institute

Department

Personal name



Funding Source

Organization

Eli Lilly Japan K.K.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Yokohama City University Medical Center

Address

4-57 Urafune, Minami-ku, Yokohama 232-0024

Tel

045-261-5656

Email

nr1@gc5.so-net.ne.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 11 Month 01 Day


Related information

URL releasing protocol

https://cspor-bc.or.jp/members/abemaciclib/

Publication of results

Unpublished


Result

URL related to results and publications

https://cspor-bc.or.jp/members/abemaciclib/

Number of participants that the trial has enrolled

180

Results

Under analyzing

Results date posted

2024 Year 01 Month 19 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Under analyzing

Participant flow

Under analyzing

Adverse events

Under analyzing

Outcome measures

Under analyzing

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 11 Month 01 Day

Date of IRB

2019 Year 12 Month 04 Day

Anticipated trial start date

2019 Year 11 Month 01 Day

Last follow-up date

2023 Year 11 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Non-interventional, minimally invasive, prospective observational study


Management information

Registered date

2019 Year 07 Month 17 Day

Last modified on

2024 Year 02 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042634


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name